Is There a Justification for Classifying GLP-1 Receptor Agonists as Basal and Prandial?

Diabetology and Metabolic Syndrome - United Kingdom
doi 10.1186/s13098-017-0204-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Combination Therapy With GLP-1 Receptor Agonists and Basal Insulin: A Systematic Review of the Literature

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2012English

The Cardiovascular Effects of GLP-1 Receptor Agonists

Cardiovascular Therapeutics
MedicineCardiovascular MedicinePharmacologyCardiology
2010English

Cardiovascular Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2014English

Extra Glycemic Impacts of GLP-1 Receptor Agonists: Benefits of a Class Effect?

Open Journal of Endocrine and Metabolic Diseases
2016English

Clinical Trial Highlights – GLP-1 Agonists

Journal of Parkinson's Disease
Molecular NeuroscienceNeurologyCellular
2020English

Role and Development of GLP-1 Receptor Agonists in the Management of Diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2009English

Β-Arrestin-Biased Agonists of the GLP-1 Receptor From Β-Amino Acid Residue Incorporation Into GLP-1 Analogues

Journal of the American Chemical Society
BiochemistryColloidCatalysisChemistrySurface Chemistry
2016English

Correction To: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults With Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine

Advances in Therapy
MedicinePharmacology
2019English

SGLT2 Inhibitors or GLP-1 Receptor Agonists as Second-Line Therapy in Type 2 Diabetes: Patient Selection and Perspectives

Vascular Health and Risk Management
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy